Last reviewed · How we verify
BIIB111
At a glance
| Generic name | BIIB111 |
|---|---|
| Also known as | Gene Therapy, AAV2-REP1 |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (PHASE3)
- A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 (PHASE2)
- Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIB111 CI brief — competitive landscape report
- BIIB111 updates RSS · CI watch RSS
- Biogen portfolio CI